AFMD | Affimed N.V. Healthcare |Biotechnology NASDAQ
📈 Technical Chart Patterns & Trend Analysis 📉
Identifying potential trading opportunities based on trend analysis:
bullish divergence can be seen oh 4h time frame
−0.8548USD
−90.388MUSD
43.461MUSD
128.332M
About Affimed N.V.
Sector
Industry
CEO
Adolf Hoess
Website
Headquarters
Heidelberg
Employees (FY)
228
Founded
2000
ISIN
NL0010872420
Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
$AFMD Pump its been a while
reasons for pump:
after a long downtrend, price has formed a base above a 3 day demand block.
price has had a bullish reaction off a triple tap of support (triple bottom).
base looks to be accumulation with a bullish divergence on the daily RSI.
unusually high v
EMA's are beginni
AFMD - Long SetupNo insiders. Looking for entry above 6.83, First target 7.83, Stop signal 6.33, 2nd target momentum.
🟢 NEW POSITION $AFMD Target 9.62 for 28.27%$AFMD Target 9.62 for 28.27%
Or double position at 5.38
This one filled in pre-market… That's a pretty decent looking chart...
—
On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average.
I start every po
$AFMD can rise in the next daysContextual immersion trading strategy idea.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany.
The demand for shares of the company looks higher than the supply.
This and other condition
AFMD: Bullish Pennant (46%)Bullish Pennant (46%)
Pros:
Volume during post formation
Descending volume during triangle formation
PPS above 50MA and 200MA
RS above 0 and ascending
ATR Ascending
R/R ratio above 6
250RSI above 50 and ascending
200MA ascending
Target:
PT = 12.10$
Help how ever you can to keep this alive.
Thank
$AFMDEntry price: 5.21
Fundamentals:
Sector: Medical
EPS % Chg (Last Qtr): 58%
3 Year EPS Growth Rate: 0%
EPS Est % Chg (Current Yr): 0%
Sales % Chg (Last Qtr): 440%
3-Year Sales Growth Rate: 163%
Annual Pre -Tax Margin: -151.3%
US Stock In Play: $AFMD (Affimed NV)$AFMD subdued an early session sell off, recovering +7.78% intraday closing above the previous day's closing at $6.79. During the month, AFMD have successfully exhibited a major MA golden cross (50D vs 100D) before the breakout to its 52 weeks high, following with a +21% runaway gap closing on Monda
AFMD macd bullish cross over signal. Target 1: 4.33 (+10%)AFMD macd bullish cross over signal. Target 1: 4.33 (+10% 70% probability of touchc within next 30 days).
Second target: 4.88
30 days expected move: 1.77
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
